Mabpharm Limited
HKEX:2181.HK
0.305 (HKD) • At close September 13, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Omzet
| 87.161 | 55.918 | 82.882 | 0 | 14.074 | 23.927 | 4.69 |
| Kosten van de omzet
| 11.923 | 15.375 | 16.777 | 0 | 0 | 0 | 0 |
| Brutowinst
| 75.238 | 40.543 | 66.105 | 0 | 14.074 | 23.927 | 4.69 |
| Brutowinstmarge
| 0.863 | 0.725 | 0.798 | 0 | 1 | 1 | 1 |
| Onderzoek- en ontwikkelingskosten
| 123.211 | 147.906 | 263.572 | 120.418 | 134.189 | 88.983 | 21.632 |
| Algemene en administratieve kosten
| 21.018 | 21.969 | 21.291 | 18.456 | 90.479 | 34.365 | 4.867 |
| Verkoop- en marketingkosten
| 48.925 | 28.213 | 9.423 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 69.943 | 50.182 | 30.714 | 18.456 | 90.479 | 34.365 | 4.867 |
| Overige kosten
| -0.192 | 41.668 | 56.477 | 24.56 | -14.074 | 1.726 | 0.326 |
| Bedrijfskosten
| 273.523 | 239.756 | 350.763 | 163.434 | 210.594 | 147.543 | 42.475 |
| Bedrijfsresultaat
| -199.693 | -203.83 | -289.268 | -180.69 | -194.834 | -148.112 | -44.378 |
| Bedrijfsresultaat ratio
| -2.291 | -3.645 | -3.49 | 0 | -13.844 | -6.19 | -9.462 |
| Totaal overige inkomsten en kosten netto
| -9.663 | -6.989 | -2.476 | -3.942 | -7.695 | -4.481 | -3.328 |
| Inkomen voor belasting
| -209.356 | -210.819 | -291.744 | -184.632 | -202.529 | -152.593 | -47.706 |
| Inkomen voor belasting ratio
| -2.402 | -3.77 | -3.52 | 0 | -14.39 | -6.377 | -10.172 |
| Belastingkosten
| 60.527 | -0.199 | 2.476 | 3.942 | 7.695 | -2.834 | -16.642 |
| Nettowinst
| -209.356 | -210.62 | -294.22 | -188.574 | -210.224 | -124.883 | -31.064 |
| Nettowinstmarge
| -2.402 | -3.767 | -3.55 | 0 | -14.937 | -5.219 | -6.623 |
| WPA (Winst Per Aandeel)
| -0.051 | -0.051 | -0.071 | -0.046 | -0.055 | -0.03 | -0.008 |
| Verwaterde WPA
| -0.051 | -0.051 | -0.071 | -0.046 | -0.055 | -0.03 | -0.008 |
| EBITDA
| -138.998 | -152.281 | -245.391 | -156.293 | -172.636 | -136.396 | -34.298 |
| EBITDA ratio
| -1.595 | -2.723 | -2.961 | 0 | -12.266 | -5.701 | -7.313 |